Trial reportAllergy2026
Codfish Oral Immunotherapy in Children Aged 2-10: Randomized Placebo-Controlled Study.
Trial report in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05590299 (A Randomised, Controlled Trial Evaluating the Effectiveness of Fish Oral Immunotherapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Controlled Trial Evaluating the Effectiveness of Fish Oral Immunotherapy (FOIT) in Inducing Desensitisation or Remission in Children With Fish Allergy Compared With Placebo
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFor young children with fish allergy, dietary avoidance is the current standard of care. We aimed to assess whether codfish oral immunotherapy (OIT) can induce desensitization or sustained unresponsiveness (SU) in this population.
methodsWe conducted a randomized, double-blind, placebo-controlled study in Hong Kong. Children aged 2-10 years reactive to codfish protein during DBPCFC were randomly assigned 1:1 to codfish OIT or placebo for 52 weeks (1000 mg daily maintenance) followed by 8 weeks avoidance. Primary outcome was desensitization at week 52; sustained unresponsiveness (SU) at week 60 was a key secondary outcome.
resultsBetween November 2022-September 2023, 70 children (median age 5.6 years) were randomized to codfish OIT (n = 35) or placebo (n = 35). At the week 52 end-of-treatment challenges, 15 (43%) OIT participants versus 4 (11%) placebo achieved desensitization (risk difference 32%, 95% CI 9%-51%; p = 0.003), with significantly greater increases in cumulative tolerated protein [median 4330 mg vs. 0 mg, p < 0.001]. At week 60, SU rates were 8 (23%) versus 3 (9%) (risk difference 14%, 95% CI -5% to 33%; p = 0.332). Codfish OIT significantly decreased codfish-specific IgE, rGad c1-specific IgE, and skin reactivity while increasing codfish-specific IgG4. The treatment demonstrated acceptable safety with minimal moderate-to-severe adverse events and epinephrine use (3% both groups), and immunological evidence of reduced cross-reactivity to salmon and catfish allergens.
conclusionsIn children with fish allergy, codfish OIT significantly increased desensitization rates compared to avoidance, though SU remained limited. The treatment demonstrated acceptable safety with predominantly mild reactions and reduced IgE cross-reactivity to other fish allergens.
trial registrationClinicalTrials.gov identifier: NCT05590299.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.